The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis ...
hidradenitis suppurativa, primary immune thrombocytopenia and lupus nephritis. The therapeutic candidate is administered through subcutaneous and intravenous routes. It is a fully human IgG1/k mAb ...
Hidradenitis suppurativa is more common among patients with Crohn disease (CD) than ulcerative colitis (UC), yet bowel obstruction affects both CD and UC.